BCCMA: Basic and Translational Mechanisms of Cancer Initiation of the Urothelium in Veterans Exposed to Carcinogens: Leveraging Artificial Neural Networks to Enhance Detection of Carcinoma in situ
BCCMA:暴露于致癌物的退伍军人尿路上皮癌症发生的基本和转化机制:利用人工神经网络增强原位癌的检测
基本信息
- 批准号:10513315
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-10-01 至 2025-09-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAppearanceArtificial IntelligenceAwardBacillus Calmette-Guerin TherapyBiological WarfareBladderBladder NeoplasmBloodCancer DetectionCarcinogensCarcinoma in SituCause of DeathCharacteristicsChemicalsClinicClinicalColorectal CancerCommunitiesCystoscopyDataData SetDetectionDiagnosisDiagnosticDiagnostic SensitivityDiagnostic SpecificityEZH2 geneEarly DiagnosisEarly treatmentEligibility DeterminationEndoscopyEnsureEnvironmental ExposureEpigenetic ProcessEpitheliumEvaluationExcisionExposure toFoundationsGeneticGenetic TranscriptionGenomicsGoalsHazardous ChemicalsHematuriaHumanImageImage AnalysisImaging technologyImmuneImmunotherapyIndolentInvadedInvasive LesionKDM1A geneKnowledgeLasersLesionLightLinkMaintenanceMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of prostateMalignant neoplasm of urinary bladderMeasuresMedical ImagingMedical centerMethodsModelingMolecularMuscleNeoplasm MetastasisOccupational ExposureOperating RoomsOperative Surgical ProceduresOpticsPPAR gammaPapillaryPathologicPathologyPatient Self-ReportPatientsPrecision therapeuticsPredictive ValuePreventionPrimary CareRadiology SpecialtyRecommendationRecording of previous eventsRecurrenceReportingResolutionRiskRoleScientistScreening for cancerScreening procedureSecond Primary NeoplasmsSmokerSmokingSmoking HistorySpecificityStagingTechnologyTestingThe Cancer Imaging ArchiveTherapeuticTimeTobacco smokeTobacco smoking behaviorTrainingTranscriptional RegulationTranslatingTransurethral ResectionUrineUrologic Surgical ProceduresUrologistUrotheliumVeteransannotation systemartificial intelligence algorithmartificial neural networkautomated segmentationbladder cancer preventionbladder carcinoma in situcancer diagnosiscancer initiationcancer riskclinical applicationdeep learning algorithmdeep learning modeldemographicsepigenetic therapyexperiencehigh riskimage guidedimaging biomarkerimprovedinhibitormicroendoscopymolecular markermultimodalitynew therapeutic targetnovel diagnosticsnovel therapeutic interventionnovel therapeuticspersonalized managementpreventresearch and developmentresponserisk stratificationscreening guidelinessegmentation algorithmsuccesssupervised learningsynergismtherapy resistanttooltransfer learningtreatment responsetumortumor progressionurinary
项目摘要
PROJECT SUMMARY ABSTRACT
Herein, a group of collaborative merit review applications (CMA) aim to advance the precision
management of bladder cancer (BCa), especially focused on the early stage initiation of urothelium as
a model of dynamic epithelial changes in response to smoking and deployment-related carcinogens.
Malignancies are the second most common cause of death among Veterans and BCa is the fourth
most common cancer in the VA. Among tumor types, 70% of BCa is confined to the superficial part of
the bladder (Stages T1, Ta, and CIS), with the remainder invasive of the muscle or metastatic. If BCas
are identified at an earlier stage, nearly all of these tumors are treatable with a combination of surgery
and intracavitary therapy. Yet, there are currently no validated or recommended screening procedures
to identify asymptomatic BCas and there are no methods to identify at-risk patients at an earlier and
more curable stage. The proposed CMAs aim to address these limitations and to significantly disrupt
BCa prevention, detection, risk stratification and precision treatment by dissecting the genetic and
molecular foundations of early stage BCa. The projects include the following: CMA1 aims to determine
the genetic and immune-suppressive landscape of CIS to identify new therapeutics and
immunotherapies. CMA2 investigates the plasticity of the urothelium to determine how PPARγ can
direct epithelial differentiation as a possible modulator of CIS. CMA3 will examine the epigenetic basis
of urothelial differentiation and the role of LSD1-inhibitor, Methysticin, as a chemopreventative agent to
restore the epigenetic imbalance of the urothelium. Finally, CMA4 will develop artificial intelligence
algorithms for enhanced cystoscopy imaging technologies or BCa detection and risk stratification.
These CMAs are linked both intrinsically among each other and extrinsically with all contributors already
supported by VA R&D with Merit Awards focused on BCa to maximize synergy and ensure success.
Rationale: More than 80% of Veterans report a history of tobacco smoking with 90% of Veterans with
BCa self-reported smokers. Unlike lung, prostate or colorectal cancer, there are no screening protocols
recommended for Veterans at risk for BCa. There is no primary care recommendation for uniform
evaluation of blood in the urine, and no urinary tests have a high negative predictive value that can
replace cystoscopy. Almost all patients with BCa develop blood in the urine at some time, but there is
often delays in pursuing an evaluation by months to years that lead to tumor progression due to lack of
referrals to urologic surgery for evaluation. Once diagnosed, the urothelium is often challenging to follow
and up 20% of invasive tumors will progress to higher stage cancer. Treatment for early stage invasive
bladder cancer is dependent on BCG immunotherapy, but BCG is frequently unavailable and
underutilized for maintenance and 30% of BCas become BCG unresponsive. Therefore, the three major
challenges for improving survival for patients with BCa are 1) early detection of high-risk tumors 2)
identification of progression to higher stage cancer and 3) treatment resistance to BCG immunotherapy.
Our preliminary data suggest that the urothelium has plasticity in early stage BCa that, if understood at
the genetic, epigenetic and molecular level, could be treated and driven to a more indolent cancer.
Based on our preliminary studies and the gaps in diagnosis and treatment we hypothesize that the
urothelium can be influenced by the state of epithelial differentiation and driven towards a more stable
state if detected at early time point.
项目摘要
在此,一组协作的价值审查应用程序(CMA)旨在提高精度
膀胱癌(BCa)的管理,特别是关注尿路上皮癌的早期启动
一种对吸烟和部署相关致癌物作出反应的动态上皮变化模型。
癌症是退伍军人中第二大常见的死亡原因,BCa是第四大
最常见的癌症。在肿瘤类型中,70%的BCa局限于浅表部分,
膀胱(T1、Ta和CIS期),其余为肌肉浸润或转移。如果BCas
在早期阶段被发现,几乎所有这些肿瘤都可以通过手术联合治疗,
和腔内治疗。然而,目前还没有经过验证或推荐的筛查程序
识别无症状的BCas,没有方法在早期识别高危患者,
更容易治愈的阶段。拟议的CMA旨在解决这些限制,并显著破坏
BCa的预防、检测、风险分层和精确治疗,
早期BCa的分子基础。这些项目包括:CMA 1旨在确定
CIS的遗传和免疫抑制景观,以确定新的治疗方法,
免疫疗法CMA 2研究了尿路上皮的可塑性,以确定PPARγ如何能够
直接上皮分化作为CIS的可能调节剂。CMA3将检查表观遗传基础
以及LSD 1抑制剂Methysticin作为一种化学预防剂,
恢复泌尿系统的表观遗传失衡最后,CMA4将开发人工智能
用于增强膀胱镜成像技术或BCa检测和风险分层的算法。
这些CMA之间既有内在的联系,又与所有贡献者有外在的联系。
在VA研发的支持下,重点关注BCa的优异奖,以最大限度地发挥协同作用并确保成功。
理由:超过80%的退伍军人报告有吸烟史,90%的退伍军人
BCA自我报告的吸烟者。与肺癌、前列腺癌或结直肠癌不同,
推荐给有BCa风险的退伍军人。没有初级保健建议的统一
尿液中的血液评估,并且没有尿液测试具有很高的阴性预测值,可以
取代膀胱镜检查。几乎所有的BCa患者在某个时候都会出现尿血,但
通常延迟数月至数年进行评估,由于缺乏足够的药物,
转诊至泌尿外科进行评估。一旦确诊,尿路感染往往是具有挑战性的后续
并且高达20%的侵袭性肿瘤会发展为更高阶段的癌症。早期侵入性的治疗
膀胱癌依赖于BCG免疫疗法,但BCG经常不可用,
未充分用于维护,30%的BCAs变得BCG无反应。因此,三大
提高BCa患者生存率的挑战是1)早期发现高危肿瘤2)
鉴定向更高阶段癌症的进展和3)对BCG免疫疗法的治疗抗性。
我们的初步数据表明,在早期BCa阶段,尿托具有可塑性,
在遗传、表观遗传和分子水平上,可以被治疗并驱动为更惰性的癌症。
根据我们的初步研究和诊断和治疗的差距,我们假设,
尿路上皮可受上皮分化状态的影响,
如果在早期时间点检测到,则说明。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOSEPH C LIAO其他文献
JOSEPH C LIAO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOSEPH C LIAO', 18)}}的其他基金
Intraoperative integration of artificial intelligence during cystoscopic surgery
膀胱镜手术中人工智能的术中整合
- 批准号:
10365872 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Intraoperative integration of artificial intelligence during cystoscopic surgery
膀胱镜手术中人工智能的术中整合
- 批准号:
10544344 - 财政年份:2022
- 资助金额:
-- - 项目类别:
BCCMA: Basic and Translational Mechanisms of Cancer Initiation of the Urothelium in Veterans Exposed to Carcinogens: Leveraging Artificial Neural Networks to Enhance Detection of Carcinoma in situ
BCCMA:暴露于致癌物的退伍军人尿路上皮癌症发生的基本和转化机制:利用人工神经网络增强原位癌的检测
- 批准号:
10260145 - 财政年份:2021
- 资助金额:
-- - 项目类别:
MagSToNE - a magnetic system for kidney stone fragment elimination
MagSToNE - 用于消除肾结石碎片的磁性系统
- 批准号:
10354258 - 财政年份:2021
- 资助金额:
-- - 项目类别:
MagSToNE - a magnetic system for kidney stone fragment elimination
MagSToNE - 用于消除肾结石碎片的磁性系统
- 批准号:
10491338 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Personalized assessment of bladder cancer treatment response using urinary molecular biomarkers
使用尿液分子生物标志物对膀胱癌治疗反应进行个性化评估
- 批准号:
10514572 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Personalized assessment of bladder cancer treatment response using urinary molecular biomarkers
使用尿液分子生物标志物对膀胱癌治疗反应进行个性化评估
- 批准号:
10293596 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Personalized assessment of bladder cancer treatment response using urinary molecular biomarkers
使用尿液分子生物标志物对膀胱癌治疗反应进行个性化评估
- 批准号:
10015540 - 财政年份:2020
- 资助金额:
-- - 项目类别:
A Droplet-based single cell platform for pathogen identification and AST
用于病原体识别和 AST 的基于 Droplet 的单细胞平台
- 批准号:
8875827 - 财政年份:2015
- 资助金额:
-- - 项目类别:
A Droplet-based single cell platform for pathogen identification and AST
用于病原体识别和 AST 的基于 Droplet 的单细胞平台
- 批准号:
9038992 - 财政年份:2015
- 资助金额:
-- - 项目类别:
相似海外基金
AMFaces: Advanced Additive Manufacturing of User-Focused Facial Prostheses with Real-Life Colour Appearance
AMFaces:以用户为中心的面部假体的先进增材制造,具有真实的色彩外观
- 批准号:
EP/W033968/1 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Research Grant
Understanding the appearance mechanism of ferroelectric liquid crystals showing spontaneous polarization in the director and developing their applications.
了解铁电液晶在指向矢中表现出自发极化的出现机制并开发其应用。
- 批准号:
23H00303 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (A)
Body, appearance, and health surveillance in female youth friendship contexts
女性青少年友谊背景下的身体、外表和健康监测
- 批准号:
2690554 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Studentship
Elucidating the mechanism in the color appearance of small-field stimulus on chromatic surroundings
阐明彩色环境中小场刺激的颜色外观机制
- 批准号:
22K20317 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Research Activity Start-up
Path-space Exploration for Light Transport and Appearance Modelling
光传输和外观建模的路径空间探索
- 批准号:
RGPIN-2018-05669 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Discovery Grants Program - Individual
Learning to Recognize Faces Despite Within-Person Variability in Appearance: A Developmental Approach
尽管人与人之间的外表存在差异,但仍要学习识别面孔:一种发展方法
- 批准号:
RGPIN-2022-04386 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Discovery Grants Program - Individual
A sociological study on appearance discrimination during employment selection
就业选择中外表歧视的社会学研究
- 批准号:
21K13447 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Appearance of negative influences of global warming on crop production and measures against it
全球变暖对农作物生产的负面影响的显现及应对措施
- 批准号:
21H02330 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (B)
The influence of river environment on urban appearance of wildlife
河流环境对野生动物城市面貌的影响
- 批准号:
21K12322 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Method for assessing women's perceptions of their appearance in the context of breast cancer care
评估乳腺癌护理背景下女性对其外表的看法的方法
- 批准号:
10196213 - 财政年份:2021
- 资助金额:
-- - 项目类别: